Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy: Secondary Analysis of the WAVE Randomized Trial

Retinal vein occlusion (RVO) is a major cause of vision loss and typically results from thrombosis of venous outflow.1 This blockage can lead to retinal nonperfusion (RNP), physiologic ischemia, and release of angiogenic factors including vascular endothelial growth factor-A (VEGF-A).The advent of VEGF antagonists such as ranibizumab (Lucentis; Genentech, South San Francisco, CA), aflibercept (Eylea; Regeneron, Tarrytown, NY), and bevacizumab (Avastin; Genentech, South San Francisco, CA) has revolutionized the treatment and management of RVO, with multiple clinical trials demonstrating their
Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - Category: Opthalmology Authors: Source Type: research